Atrix/Sanofi Eligard Monthly Could Launch In Advance Of 3-Month Version
Executive Summary
Atrix and Sanofi-Synthelabo may launch the monthly formulation of their prostate cancer therapy Eligard before the approval of the three-month formulation, which is pending at FDA, Atrix said following the Jan. 23 approval of leuprolide 7.5 mg